Massive Bio, ONCOassist Launch Strategic Partnership
Collaboration to focus on enhancing physician engagement in clinical trials and cancer research.
Massive Bio and ONCOassist have announced in a joint press release that they have entered into a strategic partnership with the aim of optimizing patient-centric care and enhancing physician engagement in clinical trials and cancer research. As a result of the joint venture, the organizations are hoping to reshape the oncology landscape.
"In the rapidly evolving realm of oncology, our partnership with ONCOassist stands as a testament to our dedication to pushing the boundaries and ensuring every cancer patient receives optimal care,” said Arturo Loaiza-Bonilla, MD, co-founder, chief medical officer, Massive Bio, in the aforementioned press release.
Reference: Massive Bio and ONCOassist® Announce Strategic Partnership at ESMO 2023. BusinessWire. October 19, 2023. Accessed October 25, 2023. https://www.businesswire.com/news/home/20231019250308/en/Massive-Bio-and-ONCOassist%C2%AE-Announce-Strategic-Partnership-at-ESMO-2023
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
CAHtalyst Trial Shows Crenessity Sustains Efficacy in Classic Congenital Adrenal Hyperplasia
July 14th 2025Results from the Phase III CAHtalyst show that patients treated with Crenessity for classic congenital adrenal hyperplasia achieved and maintained lower, more physiologic glucocorticoid doses while keeping key adrenal biomarkers at or below baseline levels.
Baxdrostat Shows Significant Blood Pressure Reduction in Phase III BaxHTN Trial
July 14th 2025In the BaxHTN Phase III study, AstraZeneca’s baxdrostat demonstrated statistically significant and clinically meaningful reductions in systolic blood pressure in patients with uncontrolled or treatment-resistant hypertension.
